Bharat in Betastartup field guide
← Back to the atlas
No. 130Opportunity areaHealth and wellbeing

Next-generation biologics platforms

Source

The idea

Support new therapeutic modalities and discovery.

Why this is interesting

  • Biologics and biosimilars depend on development, manufacturing and regulatory capability as much as discovery. The commentary pairs this mission with AI-assisted discovery, which is a tool inside the pipeline rather than a business on its own.
  • The source is Ankur Capital’s commentary on a government bioeconomy roadmap. A roadmap mission is a policy intention, not funded or proven demand, and the underlying roadmap was not separately reviewed here.

Possible starting points

01

Development services for one modality

Support process development or analytical testing for teams working on one class of biologic.

02

Discovery tooling with a paying partner

Build a discovery or screening tool with one pharmaceutical partner who defines the target and how results are judged.

Questions to answer

  1. For the intended customers, is the bottleneck discovery, process development or manufacturing capacity?
  2. Who funds the long period before a product reaches the market?
No. 1475Opportunity areaHealth and wellbeing

Affordable cell and gene therapy production platforms

Develop locally integrated manufacturing and clinical capabilities to broaden access.

No. 1703ProposalHealth and wellbeing

AI Personalized Medicine

Combine agents with diagnostic, genomic, EHR, and wearable data to personalize risk assessment and treatment as testing and individualized therapies become cheaper.

No. 1827Existing businessHealth and wellbeing

AI-driven in vivo delivery for precision medicine

Use AI to improve in vivo delivery for precision medicines.